# Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

> **NCT06895733** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 65 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Next-generation Sequencing
- Precision Medicine

## Interventions

- **DRUG:** Pazopanib Oral Tablet
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT06895733
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06895733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06895733, "Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06895733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*